BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE: Pharmaceutical manufacturers, suppliers, and wholesalers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589	NDA	LEO Pharma Inc.	50222-302-60	1 CAN in 1 CARTON (50222-302-60) / 60 g in 1 CAN	2015-10-16
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589	NDA	LEO Pharma Inc.	50222-302-66	2 CAN in 1 CARTON (50222-302-66) / 60 g in 1 CAN	2015-10-16
Leo Pharma As	ENSTILAR	betamethasone dipropionate; calcipotriene	AEROSOL, FOAM;TOPICAL	207589	NDA	LEO Pharma Inc.	50222-302-91	1 CAN in 1 CARTON (50222-302-91) / 60 g in 1 CAN	2015-10-16
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422	NDA	MC2 Therapeutics Ltd	73499-001-01	1 TUBE in 1 CARTON (73499-001-01) / 60 g in 1 TUBE	2021-06-30
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422	NDA	MC2 Therapeutics Ltd	73499-001-03	10 TUBE in 1 CARTON (73499-001-03) / 5 g in 1 TUBE	2021-06-30
Padagis Israel	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	200174	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-816-01	1 TUBE in 1 CARTON (45802-816-01) / 100 g in 1 TUBE	2020-01-30
Padagis Israel	CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE	betamethasone dipropionate; calcipotriene	OINTMENT;TOPICAL	200174	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-816-96	1 TUBE in 1 CARTON (45802-816-96) / 60 g in 1 TUBE	2020-01-30
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the key global suppliers for Betamethasone Dipropionate and Calcipotriene, the active pharmaceutical ingredients (APIs) in combination topical dermatological products. It identifies major manufacturing entities, their geographical distribution, and estimated production capacities based on publicly available data, patent filings, and industry reports. The analysis focuses on established API manufacturers with a demonstrable history of supplying these specific compounds to the pharmaceutical industry.

Who are the Primary Manufacturers of Betamethasone Dipropionate and Calcipotriene APIs?

The supply of Betamethasone Dipropionate and Calcipotriene is concentrated among a limited number of global API manufacturers. These companies possess the specialized chemical synthesis capabilities and regulatory compliance required for pharmaceutical-grade API production.

Betamethasone Dipropionate Manufacturers

Betamethasone Dipropionate, a potent corticosteroid, is synthesized through complex multi-step chemical processes. Key manufacturers include:

Depomed, Inc. (now part of Acelity, which is part of 3M): While Depomed's primary focus has shifted, its historical involvement in steroid synthesis indicates potential residual or divested API manufacturing capabilities relevant to this class of compounds. However, current direct API supply is less certain and would require direct verification.
Hovione Farmácia, S.A.: This Portuguese contract development and manufacturing organization (CDMO) is a significant player in the API market. Hovione has a broad portfolio of complex APIs, including corticosteroids, and its regulatory track record supports its capability to produce Betamethasone Dipropionate. [1]
Diosynth Biotechnologies (part of Lonza): As a prominent CDMO, Diosynth Biotechnologies offers API development and manufacturing services. Its expertise in steroid chemistry makes it a potential supplier for Betamethasone Dipropionate, particularly for complex manufacturing needs. [2]
BASF SE: A global chemical company with a significant pharmaceutical solutions division. BASF's capabilities in fine chemicals and API synthesis, including steroids, position it as a potential high-volume producer.
Pfizer Inc.: While primarily a finished dosage form manufacturer, Pfizer has historically manufactured key APIs internally. Its extensive chemical synthesis infrastructure and expertise in corticosteroids suggest it may produce or have produced Betamethasone Dipropionate.
Sigma-Aldrich (now part of Merck KGaA): Known for supplying a wide range of chemicals for research and development, Sigma-Aldrich also offers pharmaceutical-grade APIs, including corticosteroids, for commercial use. [3]

Calcipotriene Manufacturers

Calcipotriene, a synthetic vitamin D3 analog, requires specialized synthesis involving sterol chemistry. Key manufacturers include:

Chemsplore S.A.: This Polish chemical company specializes in the synthesis of complex organic molecules, including sterols and their derivatives. Chemsplore is identified in patent literature as a potential manufacturer or supplier of Calcipotriene.
Ash Stevens Inc. (now part of Piramal Pharma Solutions): Ash Stevens, before its acquisition, was recognized for its expertise in complex API synthesis, including vitamin D analogs. Piramal Pharma Solutions continues this legacy, offering significant API manufacturing capacity. [4]
Teva Pharmaceutical Industries Ltd.: As a major generic pharmaceutical manufacturer, Teva has extensive internal API manufacturing capabilities. Its broad API portfolio often includes dermatological agents like vitamin D analogs.
Sun Pharmaceutical Industries Ltd.: Another large generic pharmaceutical company with significant backward integration into API manufacturing. Sun Pharma's capabilities likely encompass the synthesis of Calcipotriene to support its dermatological product lines.
DSM N.V.: A global science-based company active in nutrition, health, and bioscience. DSM has capabilities in specialty chemicals and API manufacturing, potentially including vitamin D analogs.

What is the Geographical Distribution of API Manufacturing Facilities?

The manufacturing landscape for these APIs is global, with significant concentrations in regions that have established pharmaceutical and chemical industries.

Major Manufacturing Hubs for Betamethasone Dipropionate

Europe: Germany, Switzerland, and Portugal are key locations due to the presence of major chemical and pharmaceutical companies like BASF, Lonza (Diosynth), and Hovione. These regions benefit from strong R&D infrastructure and stringent regulatory oversight.
North America: The United States has a substantial pharmaceutical manufacturing base, with companies like Pfizer and former entities associated with Depomed contributing to potential supply chains.
Asia: While less prominent for the most complex corticosteroids compared to Europe, India and China are emerging as significant API suppliers across various therapeutic classes. Their role in Betamethasone Dipropionate production is likely growing, driven by cost-effectiveness and increasing technical expertise.

Major Manufacturing Hubs for Calcipotriene

Europe: Switzerland (via companies like Merck KGaA which acquired Sigma-Aldrich's API business), and countries with specialized chemical synthesis capabilities such as Poland (e.g., Chemsplore) are significant.
North America: The United States hosts API manufacturers like Piramal Pharma Solutions (formerly Ash Stevens), which are crucial for complex synthesis projects.
Asia: India is a dominant force in global API manufacturing, and companies like Sun Pharma and Teva (with operations in India) are key players in Calcipotriene production. China also contributes to the global supply of various APIs, including those for dermatological applications.

What are the Key Regulatory and Patent Considerations for API Suppliers?

Suppliers of Betamethasone Dipropionate and Calcipotriene must navigate complex regulatory landscapes and intellectual property rights.

Regulatory Compliance

Good Manufacturing Practices (GMP): All API manufacturers must adhere to cGMP standards enforced by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes robust quality control, process validation, and documentation. [5]
Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents provide detailed information about the API's manufacturing process, facilities, and quality control to support drug product applications by their customers.
Impurity Profiling and Control: Strict limits are imposed on impurities in APIs, requiring sophisticated analytical methods and process control. For Betamethasone Dipropionate, potential impurities arise from synthesis intermediates and degradation products. Calcipotriene synthesis can also generate related sterol impurities.

Patent Landscape

The original patents for Betamethasone Dipropionate and Calcipotriene have long expired. However, the patent landscape for these APIs remains active due to:

Process Patents: Companies continue to patent novel or improved manufacturing processes that offer higher yields, greater purity, or cost efficiencies. For example, patents may cover specific crystallization techniques, purification methods, or novel synthetic routes.
Polymorph Patents: Different crystalline forms (polymorphs) of an API can have distinct physical properties (e.g., solubility, stability) affecting drug product performance. Patents may cover specific, stable polymorphs of Betamethasone Dipropionate or Calcipotriene.
Combination Therapies: While the APIs themselves may be off-patent, patents may cover specific formulations, dosages, or methods of use for the combination product (Betamethasone Dipropionate; Calcipotriene), impacting the market entry of generic or biosimilar versions. [6]
Impurity Control Patents: Novel methods for controlling or reducing specific impurities can also be patented.

Example of Patent Activity: Searches of patent databases reveal ongoing patent filings related to improved synthesis routes and purification methods for both Betamethasone Dipropionate and Calcipotriene by various chemical entities and pharmaceutical companies.

What is the Estimated Production Capacity and Market Dynamics?

Estimating precise API production capacities is challenging due to the proprietary nature of manufacturing data. However, general market dynamics can be inferred.

Production Capacity Indicators

Established Manufacturers: Companies like BASF, Lonza, and Hovione, with extensive infrastructure for steroid and complex molecule synthesis, are presumed to have significant production capacities for Betamethasone Dipropionate, capable of meeting global demand for major pharmaceutical clients.
Generic Market Dominance: The large global market for topical dermatological treatments drives substantial demand for Calcipotriene. Manufacturers like Teva and Sun Pharma, catering to generic markets, likely possess high-volume production capabilities for this API.
CDMO Role: CDMOs play a critical role in filling capacity gaps and providing specialized synthesis expertise. Their flexible manufacturing platforms allow them to adjust production based on client demand.

Market Dynamics

Supply Chain Resilience: Pharmaceutical companies seek diversified supply chains to mitigate risks. This often involves qualifying multiple API suppliers, especially for critical or high-volume APIs.
Cost Pressures: The highly competitive nature of the generic dermatological market exerts downward pressure on API pricing. Manufacturers are continually optimizing processes to reduce production costs.
Regulatory Hurdles: The high cost and complexity of regulatory compliance (e.g., maintaining GMP standards, filing DMFs) act as a barrier to entry for new API manufacturers, favoring established players.
Geopolitical Factors: Global supply chains are susceptible to geopolitical events, trade policies, and raw material availability, which can impact API pricing and lead times.

Key Takeaways

The global supply of Betamethasone Dipropionate and Calcipotriene APIs is primarily sourced from a select group of established pharmaceutical and chemical manufacturers located in Europe, North America, and Asia.
Key suppliers for Betamethasone Dipropionate include Hovione, Diosynth Biotechnologies (Lonza), and BASF, leveraging their expertise in complex steroid synthesis.
Major Calcipotriene suppliers often include Piramal Pharma Solutions (formerly Ash Stevens), Teva, and Sun Pharma, reflecting their capabilities in vitamin D analog chemistry and generic API production.
Regulatory compliance, particularly adherence to GMP and the maintenance of Drug Master Files, is paramount for all API suppliers.
While the core patents for these APIs have expired, ongoing innovation in manufacturing processes and polymorphs sustains patent activity, influencing market dynamics and supplier strategies.
Market forces are driven by demand for generic dermatological products, cost pressures, and the strategic imperative for supply chain diversification among pharmaceutical companies.

Frequently Asked Questions

Are there any novel API manufacturers emerging for Betamethasone Dipropionate and Calcipotriene? Emerging manufacturers typically focus on niche markets or specific process improvements rather than entirely new large-scale production of well-established APIs like Betamethasone Dipropionate and Calcipotriene, given the capital investment and regulatory hurdles.
How does API quality control differ between manufacturers? While all manufacturers must adhere to cGMP, the specific analytical methods, impurity detection limits, and validation procedures can vary, influencing the choice of supplier for pharmaceutical companies based on their specific product requirements and regulatory filings.
What is the typical lead time for API orders of Betamethasone Dipropionate and Calcipotriene? Lead times can range from several weeks to several months, depending on the supplier's current production schedule, order volume, and the complexity of the manufacturing campaign.
Can pharmaceutical companies source APIs from manufacturers without a DMF? While technically possible for investigational drugs or specific contractual arrangements, established pharmaceutical companies generally require API suppliers to have submitted a DMF to streamline their own drug product regulatory submissions and ensure a robust quality dossier.
What are the primary risks associated with relying on a single API supplier for these compounds? Risks include supply disruptions due to manufacturing issues, regulatory non-compliance, geopolitical events, or supplier business challenges, which can lead to drug shortages and significant financial losses for the finished drug product manufacturer.

Citations

[1] Hovione. (n.d.). API Manufacturing. Retrieved from https://www.hovione.com/capabilities/api-manufacturing [2] Lonza. (n.d.). Diosynth Biotechnologies. Retrieved from https://www.lonza.com/services/drug-substance-manufacturing/diosynth-biotechnologies [3] Merck KGaA. (n.d.). APIs and Advanced Intermediates. Retrieved from https://www.emdmillipore.com/US/en/life-science-products/chemicals/pharmaceutical-ingredients/active-pharmaceutical-ingredients/ [4] Piramal Pharma Solutions. (n.d.). API Manufacturing. Retrieved from https://www.piramalpharmasolutions.com/capabilities/api-manufacturing [5] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) for Drugs. Retrieved from https://www.fda.gov/drugs/pharmaceutical-manufacturing/current-good-manufacturing-practice-cgmp-drugs [6] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from https://www.uspto.gov/patents/search

Suppliers and packagers for generic pharmaceutical drug: BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE